Equillium Inc (EQ)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.33-5.00%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · EQ
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -86.3% |
| Our one-year growth estimate | diamond | -54.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 31.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
EQ — private placement
Dated 2026-10-26
Other Events. As previously disclosed by the Company in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 11, 2025 (the “Private Placement 8-K”), on August 10, 2025, the Company entered into the Purchase Agreement with the Investors, pursuant to which the Company agreed to sell and issue shares (“Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and pre-funded warrants to purchase shares of Common Stock (“Warr…
Why it matters: First dosing began in October 2026. The planned data readout is about six months later, so a delay could push back the next study.
Worry ifThe study reports topline data in Q2 2027, as stated in the October update.
Less concerning ifThe Q2 2027 readout slips, or the company reports that trial dosing or follow-up is delayed.
Why it matters: A patient study would test EQ504 in ulcerative colitis. Its start depends on supportive Phase 1 results.
Supportive ifEquillium starts a study in patients with moderate to severe ulcerative colitis in the second half of 2027. The study uses a placebo control.
Worry ifBy the end of 2027, Equillium has not started the study or reports that Phase 1 results do not support it.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$325 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $984 loss on $10,000 · 9.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,281 loss on $10,000 · 62.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.